competences in rechargeable battery materials and recycling support the current industrialization of electric vehicles, and our expertise in fuel cell technologies positions us well for the next generation of emission-free mobility.

“I would also like to focus more on another opportunity for Umicore PMC: the future of chemistry and catalysis in the life science and chemical industries. Novel catalysis is enabling more efficient and shorter chemistry routes, and

combining this factor with optimized metal recycling remains key for greener chemistry. As such, we continue to work in close cooperation with industrial and academic partners to reproduce the success of metathesis and cross-coupling chemistries

Umicore PMC: new ligands, new technologies

Last December, Umicore‘s business unit Precious Metals Chemistry further expanded its cross-coupling catalyst portfolio by acquiring Ruhr-Bochum University’s YPhos ligands and catalysts technology. Cross-coupling reactions are recognized as one of the most elegant and versatile synthetic methods for preparing high-value chemicals and have become essential in the synthesis of agrochemicals, electronic chemicals, fine chemicals and pharmaceuticals. Invented by Professor Viktoria Gessner’s research group, YPhos ligands are a novel class of phosphines bearing ylide substituents with electronic and steric properties that support active transition metal catalysts, particularly in reactions where strong electron-donating ligands and steric protection of low-coordinated species are required. Compared to the currently best known phosphine catalyst systems, YPhos ligands, combined with specific palladium catalysts, have shown superior

performance in room-temperature Buchwald-Hartwig amination of aryl chlorides. In addition, they have proven highly efficient in a wide range of challenging palladium-catalyzed alpha-arylation of alkyl ketones with aryl chlorides under mild conditions. They also give excellent performance in gold- catalyzed hydroamination and hydration reactions using low catalyst loadings under mild reaction conditions. Umicore now offers a selection of YPhos ligand and catalyst systems on research and commercial scale with research quantities available from the

company’s distribution partner Merck/MilliporeSigma. Previously, in October of last year, Umicore’s business unit Precious Metals Chemistry and Merck/MilliporeSigma established an exclusive

cooperation agreement for the supply of research quantities of Umicore’s advanced homogeneous catalysts through Umicore is continuing to develop its portfolio with innovative and effective catalyst technologies, which will also be made available to the scientific community via Merck/MilliporeSigma.


alongside developing further new and more environmentally friendly applications for catalysis.”

For further information on Umicore and its various business units visit www.

Outsourcing, outsmarted.

The right CDMO makes all the difference.

Don’t risk your investment with the wrong CDMO partner. Partner smart to secure and optimize your supply chain, from API sourcing through drug product development and manufacturing, to regulatory and market intelligence services.

LGM Pharma empowers our clients with expert, customized services that accelerate safe, high-quality therapeutics to market.

Read our white paper, Five “Must Ask” Questions to Find the Right CDMO, to outsmart your outsourcing.


SMART STARTS HERE: Issue 2 • March/April 2021 LGM_PRINT AD_210x144mm.indd 1 35 1/21/21 8:49 AM

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64